Trial Profile
A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-positive/HER2-negative, Early Stage Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Taselisib (Primary) ; Letrozole
- Indications Carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms LORELEI
- Sponsors Genentech
- 08 Aug 2019 Primary endpoint of Percentage of Participants With Total pCR , Defined as Having pCR in Both Breast and Axilla, Using AJCC Staging System in PIK3CA MT Participants has not been met, according to results published in the Lancet Oncology.
- 08 Aug 2019 Primary endpoint of Percentage of Participants With Total Pathologic Complete Response (Total pCR), Defined as Having pCR in Both Breast and Axilla, Using American Joint Committee on Cancer (AJCC) Staging System has not been met, according to results published in the Lancet Oncology.
- 08 Aug 2019 Results published in the Lancet Oncology